GDNF and alcohol use disorder

Segev Barak1, Somayeh Ahmadiantehrani2, Marian L. Logrip3 & Dorit Ron4

School of Psychological Sciences and the Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel1, Institute for Mind and Biology, University of Chicago, Chicago, IL USA2, Department of Psychology, Indiana University-Purdue University Indianapolis, Indianapolis, IN USA3 and Department of Neurology, University of California San Francisco, San Francisco, CA USA4

ABSTRACT

Glial cell line-derived neurotrophic factor (GDNF) has been extensively studied for its role in the development and maintenance of the midbrain dopaminergic system, although evidence suggests that GDNF also plays a role in drug and alcohol addiction. This review focuses on the unique actions of GDNF in the mechanisms that prevent the transition from recreational alcohol use to abuse. Specifically, we describe studies in rodents suggesting that alcohol acutely increases GDNF expression in the ventral tegmental area, which enables the activation of the mitogen-activated protein kinase signaling pathway and the gating of alcohol intake. We further provide evidence to suggest that GDNF acts in the ventral tegmental area via both nongenomic and genomic mechanisms to suppress alcohol consumption. In addition, we describe findings indicating that when this endogenous protective pathway becomes dysregulated, alcohol intake levels escalate. Finally, we describe the potential use of GDNF inducers as a novel therapeutic approach to treat alcohol use disorder.

Keywords addiction, alcohol, ethanol, GDNF, mesolimbic system, nucleus accumbens, ventral tegmental area.

INTRODUCTION

Alcohol use disorder (AUD) is characterized by compulsive consumption of increasing quantities of alcohol despite detrimental consequences. AUD is a devastating, life-threatening psychiatric disorder affecting up to 15 percent of the population (Grant et al. 2017; Nutt, King, Phillips et al. 2010; Sridhar 2012; World Health Organization 2014). Loss of life, decreased workplace productivity and exacerbated healthcare costs due to illnesses associated with excessive drinking all contribute to significant societal and financial liabilities (McGinnis & Foeger 1999; Rehm 2011; Whiteford et al. 2013). Substantial relief from these burdens has been delayed, as pharmacotherapeutic approaches for the treatment of AUD, which are questionably effective, are currently very limited (Bouza et al. 2004; Koob & Volkow 2010; American Psychiatric Association 2013). Characterizing the neuroadaptations underlying the transition from controlled social drinking to compulsive, excessive alcohol intake may therefore lead to the development of improved drug treatments for AUD. Although alcohol is widely consumed worldwide, only a minority of consumers drink alcohol excessively, and an even smaller portion develop alcohol dependence (World Health Organization 2014; Grant et al. 2017). This suggests the existence of innate and/or acquired mechanisms that protect against the transition from moderate to excessive, uncontrolled, compulsive alcohol use. Here, we discuss data indicating precisely such a role for the growth factor glial cell line-derived neurotrophic factor (GDNF).

GDNF is a secreted growth factor, initially identified in a glial-derived cell line (Lin et al. 1993). Gdnf is expressed throughout the central nervous system during development, and in the adult brain, Gdnf is highly expressed in the striatum, thalamus, cortex and hippocampus (Pochon et al. 1997; Ortega-de San Luis & Pascual 2016). GDNF signals through the receptor tyrosine kinase Ret (Durbec et al. 1996), with the activation of Ret by GDNF also requiring the presence of the co-receptor GDNF family receptor α1 (GFRα1; Jing et al. 1996; Airaksinen & Saarma 2002). Ligation of GDNF to Ret and GFRα1 leads to the activation of several intracellular signaling cascades: the mitogen-activated protein kinase
(MAPK) extracellular signal-regulated kinase 1/2 (ERK1/2), the phosphatidylinositol 3-kinase, and phospholipase Cγ (PLCγ) cascades (Airaksinen & Saarma 2002; Sariola & Saarma 2003). Ex vivo and in vivo data indicate that GDNF signaling depends on the presence of GFRα1 and Ret in lipid raft compartments within the plasma membrane (Tansey et al. 2000; Paratcha et al. 2001; Tsui et al. 2015). Interestingly, Ret expression is restricted to the midbrain (Trupp et al. 1997; Glazner, Mu, & Springer 1998), whereas the distribution of GDNF and GFRα1 are much more widespread (Ortega-de San Luis & Pascual 2016). In brain regions deficient in Ret, GDNF acts through alternate receptors, such as the adhesion proteins syndecan-3 (Bespalov et al. 2011) and neuronal cell adhesion molecule (NCAM) (Paratcha, Ledda, & Ibanez 2003).

GDNF functions

GDNF has been shown to play a vital role in peripheral neuron development (Airaksinen & Saarma 2002; Bespalov & Saarma 2007). For example, GDNF is a chemoattractant in neuronal growth cones (Dudanova, Gatto, & Klein 2010), and it plays an important role in axon guidance (Bonacci et al. 2012). Moreover, GDNF promotes axonal growth of hippocampal and cortical neurons by signaling through NCAM (Paratcha et al. 2003), and promotes neurite outgrowth by signaling via syndecan-3 (Bespalov et al. 2011). GFRα1 has been reported to be important for development of cortical GABA neurons (Pozas & Ibanez 2005). GDNF also plays a role in the survival and maintenance of spinal neurons in the dorsal root ganglia (Molliver et al. 1997), and in nociception (Salio et al. 2014). Importantly, GDNF regulates the function of midbrain dopaminergic (DAergic) neurons, discussed in detail in the following section.

GDNF in the mesolimbic dopaminergic system

GDNF is produced by striatal neurons (Pochon et al. 1997; Barroso-Chinea et al. 2005) and is retrogradely transported via DAergic neurons to the midbrain, namely, the substantia nigra (Tomac et al. 1995; Kordower et al. 2000), and ventral tegmental area (VTA; Wang et al. 2010), where the Ret receptor is abundant (Trupp et al. 1997). GDNF has been shown to positively regulate DAergic activity in both nigrostriatal and mesolimbic projections (Yang et al. 2001; Wang et al. 2010; Kumar et al. 2015; Fig. 1). For example, infusion of the growth factor into the VTA rapidly increased the spontaneous activity of DA neurons, resulting in increased extracellular DA levels in the nucleus accumbens (NAc), as measured by in vivo microdialysis (Wang et al. 2010; Fig. 1). The rapid increase in DA release in the NAc is mediated by GDNF activation of the MAPK pathway (Wang et al. 2010). Likewise, MEN2B mice, in which the Ret receptor is constitutively active, show higher levels of DA in the NAc compared with WT controls (Mijatovic et al. 2007; Kopra

Figure 1 GDNF produced in the NAc is retrogradely transported by dopamine neurons to the VTA, where the GDNF receptors Ret and GFRα1 are expressed. Ligation of GDNF to its receptors in the midbrain results in the activation of ERK1/2, which in turn promotes the spontaneous firing of VTA DA neurons. Increase in the firing of DA neurons increases DA release in the NAc.
et al. 2017). Moreover, short hairpin RNA (shRNA) -mediated knockdown of Gdnf levels in the NAc suppressed, whereas intra-NAc infusion of GDNF increased, the firing rate of VTA DA neurons (Wang et al. 2010). Contrary to these findings, Ret phosphorylation of the exchange protein Vav-2 negatively regulated the trafficking and function of the DA transporter, thereby contributing to the maintenance of DA homeostasis in the mesolimbic system (Zhu et al. 2015). Together, these data demonstrate an integral role for GDNF in regulating the activity of mesolimbic DAergic neurons.

Interestingly, data obtained ex vivo suggest that, in addition to GDNF regulating DAergic activity, DA signaling regulates GDNF expression. Treatment of DAergic-like SH-SY5Y cells or rat midbrain slices with the DA D2 receptor (D2R) agonist quinpirole led to a transient increase in the expression of the DNA-binding transcription factor zinc-finger protein 268 (Zif268) (Ahmadiantehrani & Ron 2013), followed by an increase in Gdnf expression that was prevented by D2R antagonist treatment or by short hairpin RNA-mediated knockdown of Zif268. Furthermore, the D2R-mediated induction of Gdnf and Zif268 expression was dependent on Gβγ-mediated signaling, and on activation of ERK1/2. Thus, D2R activation increases the level of Zif268 via Gβγ and ERK1/2, which functions to directly upregulate Gdnf expression (Ahmadiantehrani & Ron 2013).

GDNF and psychiatric disorders

GDNF has been implicated in several neuropsychiatric disorders in which the mesolimbic system plays an important role, including depression, anxiety, stress and schizophrenia (Ibanez & Andressoo 2017). In the NAc, epigenetic modifications within the Gdnf gene have been associated with increased susceptibility to mild stressors (Uchida et al. 2011). Polymorphism within the Gdnf gene has been reported to be associated with increased risk of depression (Ma et al. 2013) and anxiety disorders (Kotyuk et al. 2013). Moreover, in a post-mortem study, GFRα1 levels were reduced in the basolateral amygdala of patients that suffered from depression and correlated with the increased expression of microRNAs that target the receptor (Maheu et al. 2015). Interestingly, serum GDNF levels have been correlated with mood assessments. For instance, levels of GDNF were lower in patients suffering from depression as compared with healthy controls (Diniz et al. 2012; Lin & Tseng 2015), and increased serum GDNF levels were reported during the manic phase in bipolar patients (Tunca et al. 2015).

Unfortunately, administration of GDNF into the cerebral ventricles had no antidepressant effects in a genetic model of depression (Naumenko et al. 2013). Notably, intracerebral administration of GDNF was shown to induce side effects in primates (Zhang et al. 1997) and human Parkinson’s disease patients (Nutt et al. 2003). Nonetheless, continued elucidation of GDNF’s contribution to psychiatric disorders is of great interest, particularly with respect to the misuse of drugs and alcohol. Finally, GDNF has been implicated as a key player in the regulation of intake of abused drugs, reward and relapse, as reviewed elsewhere (Carnicella & Ron 2009; Ghitz et al. 2010). Here, we focus on GDNF as a regulator of alcohol-drinking behaviors.

GDNF AND ALCOHOL

GDNF is an alcohol-responsive gene

Similar to other genes whose expression is altered by alcohol (Ron & Barak 2016), studies in rodents indicate that Gdnf levels fluctuate in response to different regimens of alcohol exposure. For instance, 1 week of intermittent access 2-bottle choice (IA2BC), in which rodents have concurrent access to one bottle containing 20 percent alcohol and a second bottle containing water, increased Gdnf mRNA levels in the VTA of rats when assessed at the end of the last drinking session, relative to water-only controls. Similarly, a single systemic administration of a non-hypnotic dose of alcohol increased Gdnf mRNA expression in the VTA (Ahmadiantehrani, Barak, & Ron 2014). Interestingly, the levels of Gdnf in the NAc were unaltered in response to alcohol exposure (Ahmadiantehrani et al. 2014). Gdnf expression was still elevated in the VTA when measured immediately after a 30-minute binge-like drinking session following 7 weeks of IA2BC training, as compared with rats drinking only water (Ahmadiantehrani et al. 2014). However, Gdnf levels in the VTA were reduced below baseline in response to 7 weeks of IA2BC when tested after a 24-hour withdrawal period (Ahmadiantehrani et al. 2014). Together, these findings suggest that Gdnf is an alcohol-responsive gene upregulated during short-term alcohol intake, but downregulated during withdrawal from excessive alcohol intake (Fig. 2). Notably, studies in humans reported elevated serum GDNF levels in individuals displaying mild to severe AUD (Lhullier et al. 2015), but reduced levels in alcohol-dependent individuals experiencing withdrawal (Heberlein et al. 2010), supporting the notion that the GDNF system is sensitive to voluntary alcohol intake and that dysregulation of GDNF expression can be detected across species.

GDNF is a negative regulator of alcohol intake

Interestingly, GDNF in the mesolimbic system plays a unique role in neuroadaptations underlying AUD. As Gdnf is an alcohol-responsive gene in the VTA, an essential component of the brain reward circuitry (Volkow
Morales 2015), a logical assumption was that GDNF participates in mechanisms that drive alcohol-drinking behaviors. Surprisingly, activation of the GDNF pathway in the VTA produces a very rapid and robust suppression of alcohol-drinking behaviors in rats. Specifically, infusion of recombinant GDNF (rGDNF) into the VTA reduced alcohol-reinforced lever pressing, regardless of previous levels of alcohol intake (Carnicella et al. 2008). Furthermore, rGDNF infusion into the VTA also inhibited reacquisition of operant alcohol self-administration upon renewed alcohol access in rats whose alcohol-directed operant responding had previously been extinguished (Carnicella et al. 2008), suggesting that the growth factor decreases alcohol seeking during relapse. Importantly, rGDNF did not affect the self-administration of sucrose (Carnicella et al. 2008), implying that the growth factor does not alter the general motivation to seek and consume natural rewards.

To further elucidate the role of GDNF in regulating alcohol drinking, the IA2BC procedure was employed to determine GDNF’s ability to curb binge-like drinking. Infusion of rGDNF into the VTA rapidly suppressed binge-like home cage alcohol intake, and this suppressive effect persisted 24 and even 48 hours after a single administration of the growth factor (Carnicella, Amamoto, & Ron 2009; Barak et al. 2011b). Moreover, viral-mediated overexpression of the growth factor in the NAc or VTA blocked escalation from moderate to excessive alcohol drinking, as measured in the IA2BC procedure (Barak et al. 2015). Together, these data suggest that activation of the GDNF signaling pathway in the VTA produces a robust reduction of alcohol-drinking behaviors.

To test the contribution of the endogenous GDNF system to alcohol-drinking phenotypes, GDNF expression in the VTA or NAc was knocked down by adenoviral delivery of shRNA directed against Gdnf (AdV-shGDNF). Gdnf downregulation in either the VTA or NAc facilitated the escalation of IA2BC alcohol drinking compared with rats infected with a non-specific control sequence in the same brain regions (Ahmadianehtrani et al. 2014; Barak et al. 2015). Similarly, GDNF heterozygote knockout mice, in which 50 percent of the GDNF is knocked out (Griffin et al. 2006), consumed more alcohol than their WT littermates after a period of abstinence and exhibited increased alcohol conditioned place preference (CPP), a measure of alcohol reward (Carnicella, Ahmadianehtrani, Janak et al. 2009). These findings could be linked to the observation that Gdnf heterozygote knockout mice exhibit higher levels of DA in the striatum (Airavaara et al. 2004). Taken together, these data suggest that endogenous GDNF protects against the development of excessive alcohol drinking during the early stages of alcohol consumption (Fig. 2). However, long-term, excessive alcohol intake may lead to breakdown of this protective response, resulting in the escalation of alcohol intake (Fig. 2).

Interestingly, a recent study showed that the re-exposure to a context previously associated with nicotine caused a 50 percent reduction in Gdnf expression in the VTA, coupled with pronounced and long-lasting (3 month) increases in operant alcohol self-administration and relapse (Zipori et al. 2017). These findings suggest that breakdown of the GDNF pathway is a common adaptation that may underlie co-morbidity of nicotine and alcohol misuse.

Another important piece of evidence for the crucial role of endogenous GDNF in controlling alcohol intake is the differential expression of Gdnf in low and high alcohol drinkers. Specifically, although the IA2BC procedure generally produces a high number of excessively drinking rats (approximately 60–70 percent), not all rats develop this typical pattern of alcohol consumption (Carnicella, Ron, & Barak 2014). Thus, alcohol-drinking rats can be segregated into two distinct groups: those whose alcohol intake progressively increases over

© 2018 Society for the Study of Addiction

Addiction Biology
time (excessive drinkers), and those who maintain moderate alcohol consumption (low drinkers). Interestingly, although binge-like alcohol drinking increased Gdnf expression in the VTA in both groups, the effect was considerably stronger among low drinkers (Ahmadiantehrani et al. 2014). While this effect is confounded by the fact that excessive drinkers consumed higher levels of alcohol during the binge-drinking period (Ahmadiantehrani et al. 2014), nonetheless, these results suggest that GDNF is more functional, and thus more responsive to alcohol, in low drinkers compared with excessive drinkers. This conclusion was further supported by a negative correlation between alcohol intake levels and Gdnf expression in the VTA (Barak et al. 2015), indicating that the lower Gdnf expression was, the more alcohol was consumed. Interestingly, these data are in line with human data indicating that serum GDNF is reduced in humans undergoing alcohol withdrawal (Heberlein et al. 2010), suggesting that low serum levels of GDNF may be an indicator of susceptibility to relapse. Taken together, these findings suggest that the sensitivity of the GDNF expression system to alcohol determines the profile of drinking. Thus, variation in the Gdnf gene, particularly modifications that would impair the Gdnf response to alcohol, should be investigated further as a possible marker of AUD susceptibility.

**POTENTIAL MECHANISMS OF ACTION UNDERLYING GDNF REGULATION OF ALCOHOL INTAKE**

As mentioned in the introduction, GDNF binding to the receptor tyrosine kinase Ret and the co-receptor GFRα1 can activate several downstream signaling cascades. GDNF-dependent regulation of alcohol intake is mediated by the ERK1/2 pathway in the VTA (Carnicella et al. 2008). Specifically, intra-VTA infusion of GDNF activated ERK1/2 in the VTA, and specific inhibition of the MAPK pathway, but not of PI3K-, prevented GDNF-mediated suppression of alcohol self-administration (Carnicella et al. 2008). PLCγ inhibition reduced alcohol self-administration on its own, making it impossible to conclude whether the pathway contributes to the effects of GDNF on alcohol self-administration (Carnicella et al. 2008). It is possible that protein kinase C, the downstream target of PLCγ, is activated under basal conditions, and this kinase has been implicated in the enhancement of alcohol-drinking behavior (Ron & Barak 2016). The rapid suppression of alcohol self-administration in response to intra-VTA GDNF infusion suggests that a non-genomic mechanism, such as post-translational modification, modulates alcohol drinking downstream of GDNF activation of ERK1/2 signaling. A limited number of extra-nuclear neuronal substrates for ERK1/2 have been identified, of which the A-type potassium channel Kv4.2 was shown to be phosphorylated by ERK1/2 (Adams et al. 2000; Schrader et al. 2006). ERK1/2-mediated phosphorylation of Kv4.2 results in the inhibition of channel activity, thereby increasing neuronal excitability (Schrader et al. 2006; Yuan et al. 2006). Interestingly, GDNF increased evoked firing of primary midbrain DA neurons via the inhibition of an A-type potassium channel in a MAPK-dependent manner (Yang et al. 2001), and GDNF-dependent enhancement of VTA DA neuron firing also depends on ERK1/2 (Wang et al. 2010). Further studies are required to confirm the involvement of an A-type potassium channel phosphorylation in the GDNF-dependent, ERK1/2-mediated enhancement of VTA DA neuron activity.

**Nongenomic, rapid effects of GDNF on alcohol intake**

One source of GDNF that modulates the increase in VTA DA neuron activity is the NAc, because GDNF produced in the NAc is retrogradely transported by DA VTA neurons (Wang et al. 2010; Fig. 1). Upon binding to its receptors in the VTA, GDNF produces a rapid increase in the spontaneous firing of VTA DA neurons (Wang et al. 2010; Fig. 1). The ability of GDNF to increase VTA DA neuron activity has important therapeutic implications in light of the well-established reduction in VTA DA neuronal activity during acute and protracted alcohol withdrawal (Diana et al. 1993; Bailey et al. 2001; Shen 2003; Shen, Choong, & Thompson 2007; Barak et al. 2015). Infusion of GDNF into the VTA reversed the deficiency in rat VTA DA neuron firing induced by long-term IА2BC alcohol intake, assessed 24 hours after cessation of alcohol drinking (Barak et al. 2015). Together, these results support the possibility that GDNF reduces alcohol intake by increasing VTA DA neuronal excitability, thereby reversing maladaptive changes in the VTA that may support alcohol dependence.

Decreased VTA DA neuron firing during withdrawal from chronic exposure to high levels of alcohol (Diana et al. 1993; Shen et al. 2007; Barak et al. 2015) concomitantly impacts DA release in the NAc, resulting in an allostatic reduction in NAc DA levels (Koob & Le Moal 2001; Koob 2003; Barak et al. 2011a) that has been associated with alcohol-seeking behaviors (Rossetti et al. 1992; Diana et al. 1993; Weiss et al. 1996). This relationship between reduced NAc DA input and elevated alcohol seeking suggested that GDNF might suppress alcohol consumption by reversing the alcohol withdrawal-associated DA deficiency in the mesolimbic system (Fig. 3). In line with this possibility, a single intra-VTA administration of rGDNF reversed DA overflow deficiencies in the NAc of rats following 24-hour withdrawal from
of GDNF expression. Specifically, GDNF treatment of the DAergic-like SH-SY5Y cell line induced long-lasting increases in the growth factor’s levels, resulting in long-lasting activation of Ret and Ret-mediated activation of ERK1/2 (He & Ron 2006). Furthermore, this autoregulatory positive feedback loop was observed to contribute to GDNF expression in vivo. A single infusion of rGDNF into the VTA increased the expression of GDNF mRNA and protein for at least 48 hours (Barak et al. 2011b). This long-term upregulation of Gdnf mRNA expression was eliminated by inhibition of protein synthesis, as well as by viral mediated downregulation of Gdnf mRNA using AdV-shGDNF (Barak et al. 2011b). Together, these findings indicate that GDNF positively regulates its own expression and that this process depends on de novo transcription and translation of the growth factor. Importantly, the long-lasting attenuation of excessive alcohol consumption by intra-VTA administration of GDNF was prevented by inhibition of protein synthesis, as well as by downregulation of Gdnf mRNA levels in the VTA (Barak et al. 2011b). Together, these findings suggest that GDNF can amplify and prolong its own signaling in the VTA to produce a long-lasting suppression of alcohol intake.

**Therapeutic Applications**

Given the robust effects of GDNF on alcohol-drinking behaviors, as well as the observations of abnormal circulating levels of the growth factor in humans suffering from AUDs (Heberlein et al. 2010; Lhullier et al. 2015), targeting GDNF signaling may be a novel approach for the development of new pharmacotherapies to treat AUD. One attractive pharmacological means to reduce drinking via elevated GDNF is through use of a GDNF inducer, which increases endogenous levels of GDNF to generate a long-lasting activation of GDNF signaling. Interestingly, the FDA-approved drug Cabergoline, which is prescribed for hyperprolactinemia (Webster et al. 1994), increased GDNF levels in DAergic-like SH-SY5Y cells, resulting in activation of the GDNF signaling pathway involving GDNF autoregulatory positive feedback loop was observed to contribute to GDNF expression in vivo. A single infusion of rGDNF into the VTA increased the expression of GDNF mRNA and protein for at least 48 hours (Barak et al. 2011b). This long-term upregulation of Gdnf mRNA expression was eliminated by inhibition of protein synthesis, as well as by viral mediated downregulation of Gdnf mRNA using AdV-shGDNF (Barak et al. 2011b). Together, these findings indicate that GDNF positively regulates its own expression and that this process depends on de novo transcription and translation of the growth factor. Importantly, the long-lasting attenuation of excessive alcohol consumption by intra-VTA administration of GDNF was prevented by inhibition of protein synthesis, as well as by downregulation of Gdnf mRNA levels in the VTA (Barak et al. 2011b). Together, these findings suggest that GDNF can amplify and prolong its own signaling in the VTA to produce a long-lasting suppression of alcohol intake.

**Genomic, long-term effects of GDNF on alcohol intake**

Interestingly, although GDNF-mediated reduction of alcohol intake is very rapid, it persist for a long time (Carnicella et al. 2009). Several pieces of data suggest that the GDNF-mediated reduction in alcohol intake is prolonged through an autoregulatory cycle in which the ligation of GDNF to its receptor leads to the induction of GDNF expression. Specifically, GDNF treatment of the DAergic-like SH-SY5Y cell line induced long-lasting increases in the growth factor’s levels, resulting in long-lasting activation of Ret and Ret-mediated activation of ERK1/2 (He & Ron 2006). Furthermore, this autoregulatory positive feedback loop was observed to contribute to GDNF expression in vivo. A single infusion of rGDNF into the VTA increased the expression of GDNF mRNA and protein for at least 48 hours (Barak et al. 2011b). This long-term upregulation of Gdnf mRNA expression was eliminated by inhibition of protein synthesis, as well as by viral mediated downregulation of Gdnf mRNA using AdV-shGDNF (Barak et al. 2011b). Together, these findings indicate that GDNF positively regulates its own expression and that this process depends on de novo transcription and translation of the growth factor. Importantly, the long-lasting attenuation of excessive alcohol consumption by intra-VTA administration of GDNF was prevented by inhibition of protein synthesis, as well as by downregulation of Gdnf mRNA levels in the VTA (Barak et al. 2011b). Together, these findings suggest that GDNF can amplify and prolong its own signaling in the VTA to produce a long-lasting suppression of alcohol intake.

**Figure 3** Alcohol, gial cell line-derived neurotrophic factor (GDNF) and the mesolimbic dopaminergic system. Withdrawal from excessive alcohol consumption or downregulation of GDNF in the nucleus accumbens results in deficient dopaminergic function in the mesolimbic system. This deficiency enhances alcohol seeking and intake, and alcohol temporarily alleviates the dopamine (DA) deficiency (Barak et al. 2011a). Activating the GDNF signaling pathway, either by infusion of recombinant GDNF or by overexpressing GDNF in the mesolimbic system, reverses withdrawal-induced DA deficiency and consequently suppresses alcohol seeking and drinking.

© 2018 Society for the Study of Addiction
References


Acknowledgements

The research described in and the writing of this review were supported by NIAAA P50 AA017072 (D.R.), NIAAA R37 AA016848 (D.R.); ISF 968-13 and 1916-13 (S.B.); Brain and Behavior Research Foundation NARSAD 191114 (S.B.); GIF I-2348-105.4/2014 (S.B.); the National Institute for Psychobiology in Israel (S.B.); Israel Antidrug Authority (S.B.); and NIAAA K99/R00 AA021802 (M.L.L.).

Authors Contribution

SB, SA, MLL and DR wrote the manuscript.

© 2018 Society for the Study of Addiction

Addiction Biology


